Developer docs
API playgroundTry for free, no card

Search company profiles

SaudiVax

Full company profile

uuid000dc8c

Namestring
SaudiVax
Legal namestring
SaudiVax
Websiteurl
saudivax.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

SaudiVax (SVAX) is a Saudi Arabian biotechnology company founded in 2016 and headquartered in Thuwal, with operational facilities in Riyadh and Jeddah. It operates three integrated business units: SVAX Innovation (R&D for biologics and vaccines through proprietary and co-development products), SVAX Biomanufacturing (contract development and manufacturing services including a GMP-certified secondary packaging facility in Riyadh, an aseptic filling facility under construction, and a planned drug substances facility), and SVAX Advisory Business (an SFDA-certified CRO delivering clinical operations, regulatory affairs, and biomanufacturing training programs).

The company's technology stack centers on biologics and vaccine biomanufacturing, spanning cell line development, process optimization, aseptic fill-finish, and packaging using state-of-the-art equipment and software. Supporting capabilities include an SFDA-certified regulatory affairs function that helps local and international companies navigate Saudi product registration. SVAX pursues technology transfer and localization via partnerships with Henlius, PanGen Biotech, Boehringer Ingelheim Animal Health, and Bertis, covering both human biologics and animal health vaccines.

SVAX generates revenue across a diversified mix: CMO services for biologics and vaccines, CRO/clinical operations services, regulatory affairs advisory, professional biomanufacturing training, and licensing/distribution royalties for partner products across Saudi Arabia and MENA. Customer segments are enterprise biopharma companies (local and international), regional healthcare providers, and government/public health authorities aligned with Saudi Arabia's Vision 2030 and National Biotechnology Strategy to position the Kingdom as a biomanufacturing hub serving Saudi Arabia, GCC, and OIC countries.

Short descriptiontext

SaudiVax is a Saudi Arabian biopharmaceutical company operating integrated R&D, GMP biomanufacturing, and SFDA-certified clinical and regulatory advisory services to localize vaccine and biologics production for Saudi Arabia, GCC, MENA, and OIC markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJeddah, Saudi Arabia
HQ citystring
Jeddah
HQ countrystring
Saudi Arabia
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical contract manufacturing, vaccine contract manufacturing, clinical research services, regulatory affairs consulting, biologics development services
Industry4 codes
PRIMARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAM
Training & Competency Programs for GxP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation
SECONDARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Contract Manufacturing Organization (CMO) Services
TypeManaged Services
Description

Provides cutting-edge development and manufacturing services for biologics and vaccines. State-of-the-art facilities support projects from cell line development and process optimization to fill-finish and packaging, ensuring highest quality and regulatory compliance.

saudivax.com
2Clinical Operations (CRO Services)
TypeProfessional Services
Description

SFDA-certified CRO providing end-to-end clinical trial services including study design, site selection, patient recruitment, and data management.

saudivax.com
3Regulatory Affairs Services
TypeProfessional Services
Description

Services to navigate SFDA requirements and streamline product registration for companies entering Saudi market.

saudivax.com
4Biomanufacturing Training Programs
TypeProfessional Services
Description

Specialized training programs aimed at building skilled workforce for Saudi Arabia's growing biotech industry, contributing to Vision 2030 objectives.

saudivax.com
5Product Distribution Rights
TypeLicensing Royalties
Description

Exclusive rights to register, market, and distribute partner products in Saudi Arabia and MENA countries, including technology transfer for local manufacturing.

saudivax.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SaudiVax (SVAX) is an integrated biopharmaceutical company providing end-to-end services for vaccines and biologics across three business units: SVAX Innovation (R&D of proprietary and co-developed biologics), SVAX Biomanufacturing (GMP-certified contract development and manufacturing for cell line development, process optimization, aseptic fill-finish, and packaging), and SVAX Advisory Business (SFDA-certified clinical operations, regulatory affairs, and biomanufacturing training). The company serves local and international pharmaceutical and biotech firms seeking to access the Saudi and MENA markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Position Saudi Arabia as global leader in biomanufacturing achieving self-sufficiency and equitable access to vaccines and biologics
+1 more record
Product overview1 text field

SaudiVax operates as an integrated biotechnology company offering three interconnected core business units: SVAX Innovation (R&D division for biologics and vaccines development with proprietary and co-development products), SVAX Biomanufacturing (contract development and manufacturing services including drug substance, fill-finish, and packaging facilities), and SVAX Advisory Business (SFDA-certified CRO providing clinical operations, regulatory affairs, and specialized training services). The company focuses on localizing biomanufacturing to achieve self-sufficiency in vaccines and biologics for Saudi Arabia, GCC, and OIC countries, aligned with Vision 2030.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Rubedo Life Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

SVAX announced strategic partnership with Rubedo Life Sciences during FII Week in Riyadh. SVAX will support Rubedo's regulatory filings and conduct of Phase 2 clinical trials for lead program RLS-1496 in the Kingdom of Saudi Arabia and Dubai. Partnership builds Rubedo's footprint as a Hevolution portfolio company and reflects growing strategic importance of the region in healthy longevity research.

saudivax.com
2Fakeeh Care Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SVAX and Fakeeh Care Group formed a mutually beneficial partnership built on both financial investment and strategic collaboration. Fakeeh Care Group made a strategic investment in SVAX, recognizing the company's potential to drive innovation in biopharmaceutical development and manufacturing. SVAX leverages Fakeeh's extensive network and expertise as a leading regional healthcare provider to advance R&D efforts and expand access to groundbreaking therapies.

saudivax.com
3Shanghai Henlius Biotech Inc.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SVAX and Henlius forged a strategic partnership to advance development, registration, and commercialization of innovative biopharmaceutical products in the MENAT region. Collaboration includes establishment of joint ventures focused on both commercialization and manufacturing within Saudi Arabia. Partnership aims to expand access to critical therapies and contribute to regional healthcare sector growth.

saudivax.com
4Boehringer-Ingelheim Animal Health
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SVAX and Boehringer Ingelheim Animal Health partnership aimed at enhancing livestock protection and promoting animal health in Saudi Arabia. Collaboration revolves around three key pillars: local vaccine manufacturing, scientific collaboration, and pandemic preparedness.

saudivax.com
Strategic tierCoreTypeTechnology or Integration
Description

SVAX and Sartorius collaboration leverages Sartorius's wide range of technologies and subject matter experts to deliver the first Industrial Biomanufacturing Training program in the Middle East region, in partnership with King Abdulaziz University. Collaboration supports Saudi's ambition for biomanufacturing autonomy by building a sustainable biopharmaceuticals development and manufacturing ecosystem in alignment with Vision 2030.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

SVAX signed an exclusive agreement with Bertis Inc to localize proteomics-based testing in Oncology starting with breast cancer. Utilizing the MASTOCHECK platform technology for early detection of cancer, this innovative technology will be available in Saudi Arabia and the GCC.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

SVAX and PanGen Biotech entered an Exclusive Distribution Agreement granting SVAX exclusive rights to register, market, and distribute PanGen's biopharmaceutical products in Saudi Arabia and MENA countries. PanGen provides regulatory support and FDA-approved products while SVAX manages local regulatory approvals, marketing strategies, and sales forecasts. Collaboration includes technology transfer for local manufacturing.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

SVAX partnered with King Abdulaziz University to create a specialized training program focused on development and localization of vaccines and biopharmaceuticals in Saudi Arabia. Program offers training through lectures, workshops, and hands-on experience, empowering Saudi youth with expertise needed for healthcare and biomanufacturing industries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Saudi Aramco and SVAX signed a Memorandum of Understanding to localize vaccine and biologics manufacturing in Saudi Arabia in line with Vision 2030. Saudi Aramco supports the initiative while SaudiVax focuses on developing and manufacturing. Collaboration aims to raise national awareness, attract investments, support funding applications, enhance vaccination programs, and position Saudi Arabia as a regional hub.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Syngene International
TypeDirect peer
Description

Syngene is an integrated CRO/CDMO offering discovery, development, and biologics manufacturing services. Comparable to SaudiVax's combined CRO/CMO plus R&D Innovation offering.

TypeDirect peer
Description

WuXi Biologics operates a global biologics discovery, development, and manufacturing platform (CDMO) similar to SaudiVax Biomanufacturing's CMO offering, including cell line development through fill-finish.

3Gulf Pharmaceutical Industries (Julphar)
TypeRegional player
Description

Julphar is a leading MENA-based pharmaceutical manufacturer with biologics and vaccine capabilities. A regional analog serving GCC markets for locally manufactured biologics and pharmaceuticals.

TypeBroad incumbent
Description

Catalent is a global large-scale CDMO offering biologics and sterile fill-finish services. Comparable to SaudiVax's planned aseptic filling and biologics manufacturing capabilities, although with much broader geographic reach.

TypeRegional player
Description

SPIMACO is a major Saudi pharmaceutical company manufacturing and marketing medicines locally. Comparable as a Saudi-based drug manufacturer operating under SFDA regulations, though focused on small molecules rather than biologics.

TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs serving biologics, cell and gene therapy, and small molecules. Comparable across SaudiVax's full biologics CMO stack from cell line to fill-finish.

TypeDirect peer
Description

PanGen Biotech is a Korean biopharmaceutical company focused on biosimilars and biologics. It is SaudiVax's exclusive distribution partner for Saudi Arabia and MENA, making it the closest distribution-side peer.

8Shanghai Henlius Biotech
TypeDirect peer
Description

Henlius is a Chinese biopharmaceutical company developing, manufacturing, and commercializing biosimilars and innovative mAbs. It is SaudiVax's direct JV partner for the FosunHenlius Middle East United Company, operating in the same biologics manufacturing + MENA commercialization space.

TypeDirect peer
Description

Aragen (formerly GVK BIO) is a global CRO/CDMO with biologics development and manufacturing capabilities, comparable to SaudiVax's CMO and Advisory business lines.

TypeDirect peer
Description

Samsung Biologics is a leading global CDMO offering biologics manufacturing, fill-finish, and process development. Highly comparable to SaudiVax's CMO/biomanufacturing business line for biologics and vaccines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SaudiVax

SaudiVax is a Saudi Arabian biopharmaceutical company operating integrated R&D, GMP biomanufacturing, and SFDA-certified clinical and regulatory advisory services to localize vaccine and biologics production for Saudi Arabia, GCC, MENA, and OIC markets.

What SaudiVax does

SaudiVax (SVAX) is a Saudi Arabian biotechnology company founded in 2016 and headquartered in Thuwal, with operational facilities in Riyadh and Jeddah. It operates three integrated business units: SVAX Innovation (R&D for biologics and vaccines through proprietary and co-development products), SVAX Biomanufacturing (contract development and manufacturing services including a GMP-certified secondary packaging facility in Riyadh, an aseptic filling facility under construction, and a planned drug substances facility), and SVAX Advisory Business (an SFDA-certified CRO delivering clinical operations, regulatory affairs, and biomanufacturing training programs).

The company's technology stack centers on biologics and vaccine biomanufacturing, spanning cell line development, process optimization, aseptic fill-finish, and packaging using state-of-the-art equipment and software. Supporting capabilities include an SFDA-certified regulatory affairs function that helps local and international companies navigate Saudi product registration. SVAX pursues technology transfer and localization via partnerships with Henlius, PanGen Biotech, Boehringer Ingelheim Animal Health, and Bertis, covering both human biologics and animal health vaccines.

SVAX generates revenue across a diversified mix: CMO services for biologics and vaccines, CRO/clinical operations services, regulatory affairs advisory, professional biomanufacturing training, and licensing/distribution royalties for partner products across Saudi Arabia and MENA. Customer segments are enterprise biopharma companies (local and international), regional healthcare providers, and government/public health authorities aligned with Saudi Arabia's Vision 2030 and National Biotechnology Strategy to position the Kingdom as a biomanufacturing hub serving Saudi Arabia, GCC, and OIC countries.

SaudiVax firmographics

Firmographics
Name
SaudiVax
Legal name
SaudiVax
Website
https://saudivax.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
SaudiVax is a Saudi Arabian biopharmaceutical company operating integrated R&D, GMP biomanufacturing, and SFDA-certified clinical and regulatory advisory services to localize vaccine and biologics production for Saudi Arabia, GCC, MENA, and OIC markets.
Ownership category
akta.pro rank

SaudiVax industry classification

Industry
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAM
Training & Competency Programs for GxP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation
SECONDARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Biopharmaceutical contract manufacturing
  • Vaccine contract manufacturing
  • Clinical research services
  • Regulatory affairs consulting
  • Biologics development services

Where SaudiVax is headquartered

Location

Headquarters

HQ city
Jeddah
HQ country
Saudi Arabia
HQ region
Middle East

Offices2 records

Markets served

SaudiVax business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Organization (CMO) Services: Provides cutting-edge development and manufacturing services for biologics and vaccines. State-of-the-art facilities support projects from cell line development and process optimization to fill-finish and packaging, ensuring highest quality and regulatory compliance.
  2. Clinical Operations (CRO Services): SFDA-certified CRO providing end-to-end clinical trial services including study design, site selection, patient recruitment, and data management.
  3. Regulatory Affairs Services: Services to navigate SFDA requirements and streamline product registration for companies entering Saudi market.
  4. Biomanufacturing Training Programs: Specialized training programs aimed at building skilled workforce for Saudi Arabia's growing biotech industry, contributing to Vision 2030 objectives.
  5. Product Distribution Rights: Exclusive rights to register, market, and distribute partner products in Saudi Arabia and MENA countries, including technology transfer for local manufacturing.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

SaudiVax product offering

Product offering

Core offering

SaudiVax (SVAX) is an integrated biopharmaceutical company providing end-to-end services for vaccines and biologics across three business units: SVAX Innovation (R&D of proprietary and co-developed biologics), SVAX Biomanufacturing (GMP-certified contract development and manufacturing for cell line development, process optimization, aseptic fill-finish, and packaging), and SVAX Advisory Business (SFDA-certified clinical operations, regulatory affairs, and biomanufacturing training). The company serves local and international pharmaceutical and biotech firms seeking to access the Saudi and MENA markets.

Product overview

SaudiVax operates as an integrated biotechnology company offering three interconnected core business units: SVAX Innovation (R&D division for biologics and vaccines development with proprietary and co-development products), SVAX Biomanufacturing (contract development and manufacturing services including drug substance, fill-finish, and packaging facilities), and SVAX Advisory Business (SFDA-certified CRO providing clinical operations, regulatory affairs, and specialized training services). The company focuses on localizing biomanufacturing to achieve self-sufficiency in vaccines and biologics for Saudi Arabia, GCC, and OIC countries, aligned with Vision 2030.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Position Saudi Arabia as global leader in biomanufacturing achieving self-sufficiency and equitable access to vaccines and biologics
  • +1 more outcomes

Companies that use SaudiVax

Customer profile

Segments3 records

Ideal customer profiles3 records

SaudiVax technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SaudiVax partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • Rubedo Life SciencescoreStrategic or Co-development Partner · 29 October 2025SVAX announced strategic partnership with Rubedo Life Sciences during FII Week in Riyadh. SVAX will support Rubedo's regulatory filings and conduct of Phase 2 clinical trials for lead program RLS-1496 in the Kingdom of Saudi Arabia and Dubai. Partnership builds Rubedo's footprint as a Hevolution portfolio company and reflects growing strategic importance of the region in healthy longevity research.
  • Fakeeh Care GroupcoreStrategic or Co-development PartnerSVAX and Fakeeh Care Group formed a mutually beneficial partnership built on both financial investment and strategic collaboration. Fakeeh Care Group made a strategic investment in SVAX, recognizing the company's potential to drive innovation in biopharmaceutical development and manufacturing. SVAX leverages Fakeeh's extensive network and expertise as a leading regional healthcare provider to advance R&D efforts and expand access to groundbreaking therapies.
  • Shanghai Henlius Biotech Inc.coreStrategic or Co-development PartnerSVAX and Henlius forged a strategic partnership to advance development, registration, and commercialization of innovative biopharmaceutical products in the MENAT region. Collaboration includes establishment of joint ventures focused on both commercialization and manufacturing within Saudi Arabia. Partnership aims to expand access to critical therapies and contribute to regional healthcare sector growth.
  • Boehringer-Ingelheim Animal HealthcoreStrategic or Co-development PartnerSVAX and Boehringer Ingelheim Animal Health partnership aimed at enhancing livestock protection and promoting animal health in Saudi Arabia. Collaboration revolves around three key pillars: local vaccine manufacturing, scientific collaboration, and pandemic preparedness.
  • Sartorius AGcoreTechnology or IntegrationSVAX and Sartorius collaboration leverages Sartorius's wide range of technologies and subject matter experts to deliver the first Industrial Biomanufacturing Training program in the Middle East region, in partnership with King Abdulaziz University. Collaboration supports Saudi's ambition for biomanufacturing autonomy by building a sustainable biopharmaceuticals development and manufacturing ecosystem in alignment with Vision 2030.
  • Bertis Inc.coreOEM/ Whitelabel/ Licensing PartnerSVAX signed an exclusive agreement with Bertis Inc to localize proteomics-based testing in Oncology starting with breast cancer. Utilizing the MASTOCHECK platform technology for early detection of cancer, this innovative technology will be available in Saudi Arabia and the GCC.
  • PanGen Biotech Inc.coreChannel Partner/ Reseller/ DistributorSVAX and PanGen Biotech entered an Exclusive Distribution Agreement granting SVAX exclusive rights to register, market, and distribute PanGen's biopharmaceutical products in Saudi Arabia and MENA countries. PanGen provides regulatory support and FDA-approved products while SVAX manages local regulatory approvals, marketing strategies, and sales forecasts. Collaboration includes technology transfer for local manufacturing.
  • King Abdulaziz UniversitycoreImplementation/ SI/ Consulting PartnerSVAX partnered with King Abdulaziz University to create a specialized training program focused on development and localization of vaccines and biopharmaceuticals in Saudi Arabia. Program offers training through lectures, workshops, and hands-on experience, empowering Saudi youth with expertise needed for healthcare and biomanufacturing industries.
  • Saudi Aramco (Namaat)coreStrategic or Co-development PartnerSaudi Aramco and SVAX signed a Memorandum of Understanding to localize vaccine and biologics manufacturing in Saudi Arabia in line with Vision 2030. Saudi Aramco supports the initiative while SaudiVax focuses on developing and manufacturing. Collaboration aims to raise national awareness, attract investments, support funding applications, enhance vaccination programs, and position Saudi Arabia as a regional hub.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

SaudiVax competitors and assessment

Company assessment

Direct peers

  • Syngene International: Syngene is an integrated CRO/CDMO offering discovery, development, and biologics manufacturing services. Comparable to SaudiVax's combined CRO/CMO plus R&D Innovation offering.
  • WuXi Biologics: WuXi Biologics operates a global biologics discovery, development, and manufacturing platform (CDMO) similar to SaudiVax Biomanufacturing's CMO offering, including cell line development through fill-finish.
  • PanGen Biotech: PanGen Biotech is a Korean biopharmaceutical company focused on biosimilars and biologics. It is SaudiVax's exclusive distribution partner for Saudi Arabia and MENA, making it the closest distribution-side peer.
  • Shanghai Henlius Biotech: Henlius is a Chinese biopharmaceutical company developing, manufacturing, and commercializing biosimilars and innovative mAbs. It is SaudiVax's direct JV partner for the FosunHenlius Middle East United Company, operating in the same biologics manufacturing + MENA commercialization space.
  • Aragen Life Sciences: Aragen (formerly GVK BIO) is a global CRO/CDMO with biologics development and manufacturing capabilities, comparable to SaudiVax's CMO and Advisory business lines.
  • Samsung Biologics: Samsung Biologics is a leading global CDMO offering biologics manufacturing, fill-finish, and process development. Highly comparable to SaudiVax's CMO/biomanufacturing business line for biologics and vaccines.

Regional players

  • Gulf Pharmaceutical Industries (Julphar): Julphar is a leading MENA-based pharmaceutical manufacturer with biologics and vaccine capabilities. A regional analog serving GCC markets for locally manufactured biologics and pharmaceuticals.
  • SPIMACO Addwaeih: SPIMACO is a major Saudi pharmaceutical company manufacturing and marketing medicines locally. Comparable as a Saudi-based drug manufacturer operating under SFDA regulations, though focused on small molecules rather than biologics.

Broad incumbents

  • Catalent: Catalent is a global large-scale CDMO offering biologics and sterile fill-finish services. Comparable to SaudiVax's planned aseptic filling and biologics manufacturing capabilities, although with much broader geographic reach.
  • Lonza Group: Lonza is one of the world's largest CDMOs serving biologics, cell and gene therapy, and small molecules. Comparable across SaudiVax's full biologics CMO stack from cell line to fill-finish.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

SaudiVax social profiles

Digital presence

SaudiVax compliance and trust

Trust signal

Compliance1 record

SaudiVax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SaudiVax leadership team

Management profile

Number of profiles

SaudiVax funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SaudiVax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SaudiVax

What does SaudiVax do?

SaudiVax (SVAX) is an integrated biopharmaceutical company providing end-to-end services for vaccines and biologics across three business units: SVAX Innovation (R&D of proprietary and co-developed biologics), SVAX Biomanufacturing (GMP-certified contract development and manufacturing for cell line development, process optimization, aseptic fill-finish, and packaging), and SVAX Advisory Business (SFDA-certified clinical operations, regulatory affairs, and biomanufacturing training). The company serves local and international pharmaceutical and biotech firms seeking to access the Saudi and MENA markets.

Is SaudiVax a public or private company?

SaudiVax is a private company. It is currently operating.

When was SaudiVax founded?

SaudiVax was founded in 2016. It employs 11 to 50 people.

Where is SaudiVax based?

SaudiVax is headquartered in Jeddah, Saudi Arabia, in the Middle East region.

How does SaudiVax make money?

Five revenue lines are on record. Contract Manufacturing Organization (CMO) Services are the primary driver. The others are clinical Operations (CRO Services), regulatory Affairs Services, biomanufacturing Training Programs and product Distribution Rights.

Who are SaudiVax's main competitors?

Direct peers on record are Syngene International, WuXi Biologics, PanGen Biotech, Shanghai Henlius Biotech, Aragen Life Sciences and Samsung Biologics. Regional players are Gulf Pharmaceutical Industries (Julphar) and SPIMACO Addwaeih. Broad incumbents are Catalent and Lonza Group.

Does SaudiVax have an API?

No public API is recorded for SaudiVax.

What industry is SaudiVax in?

Its primary akta.pro industry code is HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight), with a secondary code of HLAGAKAM, Training & Competency Programs for GxP Compliance. Its NAICS code is 54171 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales